Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance RangeGlobeNewsWire • 05/03/23
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide surveyGlobeNewsWire • 04/19/23
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State CertificationGlobeNewsWire • 04/18/23
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment ProgramGlobeNewsWire • 04/12/23
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United StatesPRNewsWire • 03/02/23
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGCGlobeNewsWire • 03/01/23
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® VolumesGlobeNewsWire • 02/28/23
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic TestingGlobeNewsWire • 02/07/23
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal AbnormalitiesGlobeNewsWire • 01/05/23